High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Shames, David S ^a   Carbon, Juliet ^a   Walter, Kim ^a   Jubb, Adrian M ^a   Kozlowski, Cleopatra ^a   Januario, Tom ^a   An, Do ^a   Fu, Ling ^a   Xiao, Yuanyuan ^a   Raja, Rajiv ^a   Jiang, Brittany ^a   Malekafzali, Ashi ^a   Stern, Howard ^a   Settleman, Jeff ^a   Wilson, Timothy R ^a   Hampton, Garret M ^a   Yauch, Robert L ^a   Pirzkall, Andrea ^a   Amler, Lukas C ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 3; NEU DIFFERENTIATION FACTOR;

ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GENE EXPRESSION; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; NEUREGULIN-1; RECEPTOR, ERBB-3; TUMOR MARKERS, BIOLOGICAL;

EID: 84874544754     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056765     Document Type: Article

References (20)

1. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
2. Baselga J, Swain SM, (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature reviews Cancer 9: 463-475.
3. Lefebvre JL, (2005) Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol 16Suppl 6: vi7-vi12.
4. Leemans CR, Braakhuis BJ, Brakenhoff RH, (2011) The molecular biology of head and neck cancer. Nature reviews Cancer 11: 9-22.
5. Morgan S, Grandis JR, (2009) ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res 315: 572-582.
6. Kalyankrishna S, Grandis JR, (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666-2672.
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine 354: 567-578.
8. Cohen EEW, Davis DW, Karrison TG, Seiwert TY, Wong SJ, et al. (2009) Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. The Lancet Oncology 10: 247-257.
9. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, et al. (2009) Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 27: 1864-1871.
10. del Campo JM, Hitt R, Sebastian P, Carracedo C, Lokanatha D, et al. (2011) Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 105: 618-627.
11. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J, (2011) Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 20: 158-172.
12. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, et al. (2011) A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer cell 20: 472-486.
13. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, et al. (1992) Identification of heregulin, a specific activator of p185erbB2. Science 256: 1205-1210.
14. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, et al. (1994) Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. The Journal of biological chemistry 269: 14661-14665.
15. Cervantes-Ruiperez A, Juric D, Hidalgo M, Messersmith WA, Blumenschein GR, et al. (2012) A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts. ASCO Meeting Abstracts 30: 2568.
16. Dempster AP, Laird NM, Rubin DB, (1977) Maximum Likelihood from Incomplete Data Via Em Algorithm. Journal of the Royal Statistical Society Series B-Methodological 39: 1-38.
17. Benaglia T, Chaiveau D, Hunter DR, Young D, (2009) mixtools: An R Package for Analyzing Finite Mixture Models. Journal of Statistical Software 32: 1-29.
18. Walter K, Holcomb T, Januario T, Du P, Evangelista M, et al. (2012) DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res 18: 2360-2373.
19. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157.
20. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160.